SCHEMBL23925371

SCHEMBL23925371

Oc1nc2ncnn2c(O)c1-c1ccccc1.[NaH]

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.48
ALDH1A1 P00352 6/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 3/20 0.47
MAPK1 P28482 2/20 0.47
POLB P06746 2/20 0.43
HPGD P15428 2/20 0.43
TSHR P16473 1/20 0.43
GAA P10253 3/20 0.39
LMNA P02545 2/20 0.39
GLA P06280 1/20 0.39
MDM2 Q00987 1/20 0.39
EGLN2 Q96KS0 1/20 0.38
PKM P14618 1/20 0.38
UBE2M P61081 2/20 0.37
DCUN1D1 Q96GG9 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL868954 0.98 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2MAPTMAPK1
SCHEMBL14506996 0.83 KDM4E (0.52) KDM4EALDH1A1SMN1; SMN2MAPTMAPK1
SCHEMBL4706968 0.80 EGLN2 (0.53) EGLN2
SCHEMBL14270922 0.78 EGLN2 (0.44) KDM4EALDH1A1SMN1; SMN2MAPTMAPK1
SCHEMBL13920262 0.77 USP2 (0.41) KDM4EALDH1A1MAPTMAPK1HPGD
SCHEMBL7493866 0.76 KDM4E (0.35) KDM4EALDH1A1SMN1; SMN2MAPTMAPK1
SCHEMBL2589386 0.73 ENPP1 (0.53) SMN1; SMN2MAPTMAPK1TSHRGAA
SCHEMBL8482695 0.72 KDM4E (0.38) KDM4EALDH1A1SMN1; SMN2MAPTMAPK1
SCHEMBL2964669 0.72 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2MAPTMAPK1
SCHEMBL7009613 0.72 PDE2A (0.38) ALDH1A1SMN1; SMN2MAPK1POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167121-A1 SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-06-01 US disclosed
EP-4136089-A1 SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES The Trustees of The University of Pennsylvania (US) 2023-02-22 EP disclosed
WO-2021211408-A1 SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167121-A1 SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES MAPT, TUBA4A, MAP4 KDM4E 2730/4885ALDH1A1 2113/4885SMN1; SMN2 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.